Alnylam Pharmaceuticals ALNY Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $205.99M+1,229% | $111.54M+233% | $251.08M+325% | -$66.28M-292% | -$18.25M+72.3% | ||
| $13.55M-5.9% | $13.51M-4.7% | $13.8M-1.3% | $13.94M-7.1% | $14.41M+6.6% | ||
| $70.15M+23.7% | $71.63M-21.8% | $108.21M+136% | $111.68M+25.1% | $56.71M+25.1% | ||
| $110.42M+1,385% | —— | $399.86M+978% | $136.91M+1,520% | $7.43M+1,913% | ||
| $3.32M+153% | —— | -$4.98M+16.0% | -$11.14M-64.0% | -$6.22M-28,150% | ||
| -$176.03M-11.6% | —— | $223.51M+167% | $184.15M+147% | -$157.74M-3,142% | ||
| $6.32M-80.7% | $70.99M+381% | $20.74M+151% | $0+100% | $32.77M-56.6% | ||
| $2.99M+115% | —— | —— | -$18.51M-57.1% | -$19.35M-197% | ||
| -$1.63M+94.0% | $0+100% | -$12.54M-301% | -$13.08M+93.2% | -$27.32M+4.3% | ||
| $0+100% | —— | —— | -$1.35M+1.2% | -$956K-1,326% | ||
| $70.5M+159% | $163.56M+273% | $325.11M+644% | $155.73M+25.4% | -$120.31M-47.6% | ||
| $21.83M+143% | $23.29M+156% | $12.14M+190% | $14.29M+78.3% | $8.97M-30.9% | ||
| $261.63M-34.9% | $235.91M-51.5% | $207.97M-51.7% | $459.56M+54.4% | $401.64M-4.4% | ||
| -$25.54M-122% | $0+100% | $501.11M+1,757% | -$141.38M— | $113.77M+268% | ||
| $13.16M-73.3% | $41.7M+14.9% | $77.74M-28.0% | $81.22M-38.8% | $49.37M+90.9% | ||
| -$9K— | —— | —— | —— | $0— | ||
| $15.71M-65.9% | —— | -$448.35M-536% | $51.76M-60.6% | $46.08M+59.4% | ||
| -$7.06M-150% | —— | —— | $27.51M+982% | $14.06M+241% | ||
| $53.61M0.0% | $166.01M— | $376.94M+187% | $93.61M-67.3% | $53.6M+141% | ||
| $64.2M-6.9% | $113.32M+819% | $23.89M+48.0% | $12.57M+54.1% | $68.93M+123% | ||
| $2.37M-20.2% | —— | $1.28M-72.3% | —— | $2.97M+49.4% | ||
| $0+100% | —— | —— | -$1.35M+1.2% | -$956K-1,326% | ||
| $6.32M-80.7% | $70.99M+381% | $20.74M+151% | $0+100% | $32.77M-56.6% | ||
| —— | $59.6M+87.5% | $59.6M+87.5% | $59.6M+87.5% | $59.6M+87.5% | ||
| $66.24M+21.3% | —— | $40.86M+33.0% | $16.81M-43.1% | $54.63M+73.1% | ||
| $48.83M0.0% | $0— | $1.7M— | $9.25M-48.3% | $48.83M+22.1% | ||
| $13.16M-73.3% | $41.7M+14.9% | $77.74M-28.0% | $81.22M-38.8% | $49.37M+90.9% | ||
| —— | $1.5M— | $1.5M— | $1.5M— | $1.5M— | ||
| -$9K— | —— | —— | —— | $0— | ||
| $6M— | —— | —— | —— | $0— | ||
| $3.43M+4.6% | —— | —— | —— | $3.28M— | ||
| $4.1M-91.6% | $0— | $1.7M-91.1% | $9.25M-48.3% | $48.83M+22.1% | ||
| $0-100% | $8.82M— | $3.84M+98.1% | $0-100% | $9.83M+1,170% | ||
| $2.37M-20.2% | —— | $1.28M-72.3% | —— | $2.97M+49.4% | ||
| $48.67M+138% | $140.26M+235% | $312.97M+692% | $141.44M+21.8% | -$129.28M-36.8% | ||
| $48.67M+138% | $140.26M+235% | $312.97M+692% | $141.44M+21.8% | -$129.28M-36.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Alnylam Pharmaceuticals generate?
- Alnylam Pharmaceuticals (ALNY) generated $714.9M in operating cash flow over the trailing twelve months.
- What is Alnylam Pharmaceuticals's free cash flow?
- After $71.6M of capital expenditures, Alnylam Pharmaceuticals's free cash flow was $643.3M over the trailing twelve months, up 931.4% year over year.
- Where does Alnylam Pharmaceuticals's cash flow data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
